CSPC Pharmaceutical Group Ltd HKEX:1093:
PHARMA ENTERS COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR SIRNA DRUGS
PHARMA RETAINS RIGHTS TO ONE PCC IN CHINA
ENTERING INTO COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ASTRAZENECA FOR DEVELOPMENT OF SIRNA DRUGS
PHARMA TO RECEIVE $30 MILLION UPFRONT, UP TO $540 MILLION DEVELOPMENT AND $1.2 BILLION SALES MILESTONES
ASTRAZENECA HAS OPTION FOR EXCLUSIVE GLOBAL OR EX-CHINA RIGHTS FOR EACH PCC PROGRAM